Fiche publication
Date publication
décembre 2018
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher
,
Pr CONROY Thierry
Tous les auteurs :
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB,
Lien Pubmed
Résumé
Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemotherapy, Adjuvant, Deoxycytidine, adverse effects, Disease-Free Survival, Drug Combinations, Female, Fluorouracil, adverse effects, Humans, Leucovorin, adverse effects, Lung Diseases, Interstitial, chemically induced, Male, Middle Aged, Organometallic Compounds, adverse effects, Pancreatic Neoplasms, drug therapy, Proportional Hazards Models, Prospective Studies
Référence
N. Engl. J. Med.. 2018 Dec 20;379(25):2395-2406
